News
OCUL
--
0.00%
--
BRIEF-Ocular Therapeutix Updates Monthly In-Market Unit Sales of Dextenza Billable Inserts
reuters.com · 3d ago
Ocular Therapeutix(TM) Updates Monthly In-Market Unit Sales of DEXTENZA(R) Billable Inserts
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported in-market unit sales of DEXTENZA(R) billable i...
Business Wire · 3d ago
Ocular Therapeutix™ Updates Monthly In-Market Unit Sales of DEXTENZA® Billable Inserts
BEDFORD, Mass., September 13, 2021--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported in-market ...
Business Wire · 3d ago
JMP Securities Adjusts Ocular Therapeutix's Price Target to $33 from $30, Keeps Market Outperform Rating
MT Newswires · 09/09 13:08
JMP Securities Maintains Market Outperform on Ocular Therapeutix, Raises Price Target to $33
JMP Securities analyst Jonathan Wolleben maintains Ocular Therapeutix (NASDAQ:OCUL) with a Market Outperform and raises the price target from $30 to $33.
Benzinga · 09/09 12:16
Ocular Therapeutix(TM) to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the H.C. Wainwright 23...
Business Wire · 09/07 12:00
Investing in Ocular Therapeutix (NASDAQ:OCUL) five years ago would have delivered you a 61% gain
Ocular Therapeutix, Inc. ( NASDAQ:OCUL ) shareholders might be concerned after seeing the share price drop 27% in the...
Simply Wall St. · 09/06 16:18
Rubric Capital Management LP Buys Golar LNG, Arconic Corp, Karyopharm Therapeutics Inc, Sells ...
GuruFocus News · 08/17 16:38
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2021
 
Benzinga · 08/10 14:32
FCEL, MVST and ASTR among pre market gainers
Lightning eMotors ZEV +44% on signing largest contract ever in the electric shuttle bus market with Forest River Fulcrum Therapeutics FULC +53% on early-stage results for sickle cell disease therapy IMV IMV +39% on promising maveropepimut-S
Seekingalpha · 08/10 12:55
Ocular Therapeutix™ to Present at the H.C. Wainwright Ophthalmology Virtual Conference
BEDFORD, Mass., August 10, 2021--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will...
Business Wire · 08/10 12:00
HC Wainwright & Co. Upgrades Ocular Therapeutix to Buy, Announces $17 Price Target
HC Wainwright & Co. analyst Yi Chen upgrades Ocular Therapeutix (NASDAQ:OCUL) from Neutral to Buy and announces $17 price target.
Benzinga · 08/10 10:27
--HC Wainwright Upgrades Ocular Therapeutix to Buy From Neutral; Price Target is $17
MT Newswires · 08/10 07:33
Tiff Advisory Services Inc Buys Upstart Holdings Inc, Vanguard Financials ETF, Real Estate ...
GuruFocus News · 08/10 04:38
Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates
Zacks.com · 08/09 21:25
Ocular Therapeutix Q2 EPS $(0.25) Misses $(0.21) Estimate, Sales $11.72M Beat $11.60M Estimate
Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.21) by 19.05 percent. This is a 60.94 percent increase over losses of $(0.64) per share
Benzinga · 08/09 20:23
BRIEF-Ocular Therapeutix™ Reports Second Quarter 2021 Financial Results And Business Update
reuters.com · 08/09 20:05
-- Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q2 Revenue $11.7M, vs. Street Est of $11.5M
MT Newswires · 08/09 16:20
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the...
Benzinga · 08/08 14:03
Ocular Therapeutix, Regeneron Cull Aflibercept Agreement For Retinal Diseases
Benzinga · 08/06 14:09
Webull provides a variety of real-time OCUL stock news. You can receive the latest news about Ocular through multiple platforms. This information may help you make smarter investment decisions.
About OCUL
Ocular Therapeutix, Inc. is a biopharmaceutical company, which is focused on the formulation, development and commercialization of therapies for diseases and conditions of the eye using its proprietary, bioresorbable hydrogel platform technology. The Company’s product pipeline candidates provide differentiated drug delivery solutions. The Company’s products include dexamethasone insert (DEXTENZA) and ReSure Sealant. Its DEXTENZA is an intracanalicular insert for the treatment of post-surgical ocular inflammation and pain. Its ReSure Sealant is an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery. The Company’s products that are in pipeline include OTX-TKI for the treatment of wet AMD, OTX-TIC for the treatment of glaucoma and ocular hypertension, OTX-CSI for the chronic treatment of dry eye disease, and OTX-DED for the short-term treatment of the signs and symptoms of dry eye disease.